Evanicumab Benefits Genotypes of Severe Hypertriglyceridemia
New phase 2 data show the potential of the biologic in patients at risk of acute pancreatitis progression, but with a need for better variable understanding.
Investigative biologic evanicumab was associated with substantial reduction of fasting triglyceride levels in patients with severe hypertriglyceridemia, according to new findings from a phase 2 trial.
In outcomes from a 12-week double-blind study, presented at the American College of Cardiology (ACC) 2021 Scientific Sessions this weekend, investigators reported the Regeneron Pharmaceuticals agent evanicumab provided a median reduction of 805.8 (95% CI, -1763.0 to -219.8) mg/dL triglycerides over 12 weeks in patients with the severe form of disease, which drives likelihood of acute pancreatitis.
Attending ACC 2021? Share your thoughts on the meeting, and the state of cardiology, with our 2-minute survey!
The 56.6% median reduction in such levels is contrasted against an observed median 50.7 mg/dL (1.8%) increase among patients administered placebo in the same time period (P = .0002).
That said, the findings come with stipulation that evanicumab benefit was highly dependent on patient genotype, and with the need for improved understanding of patient heterogenous response to the promising biologic.
In an interview with HCPLive during ACC 2021, study author RobertS. Rosenson, MD, of the Icahn School of Medicine at Mount Sinai, discussed the late-breaking clinical trial findings, and the currently understood profile of evanicumab for patients with hypertriglyceridemia.
The study, A Phase 2 Trial Of The Efficacy And Safety Of Evinacumab In Patients With Severe Hypertriglyceridemia,” was presented at ACC 2021.
